Use of Nanoparticles as Therapy for Respiratory Syncytial Virus Inhibition

, , , , , , , ,

Keywords: , , , ,

Respiratory Syncytial Virus is the leading cause of severe respiratory illnesses such as bronchiolitis and pneumonia in young children. RSV is a paramyxovirus with negative-sense genomic RNA that encodes for eleven proteins, two of which, F and G are major surface proteins. In the present study, we synthesized and used various nanoparticles with and without capping agents to study the inhibition of RSV infection in human cell lines. We used silver, gold and chitosan nanoparticles. Nanoparticles were conjugated to various proteins, DNA as well as poly lactic acid, to study the inhibition of RSV infection in human cell lines. The characteristics of nanoparticles were evaluated by SEM (scanning electron microscopy), TEM (transmission electron microscopy, and EAD analysis. Cell cytotoxicity of each of the nanoparticle was established and the effectiveness of RSV inhibition was evaluated by microscopic examination for syncytia formation and by immunofluorescence microscopy. Our preliminary results revealed that PVP-coated silver nanoparticles inhibited RSV infection by 44%, a significant reduction compared to other controls. Based on our preliminary results, nanoparticles seem to be a promising candidate for future RSV treatment research in animal models.

PDF of paper:

Journal: TechConnect Briefs
Volume: 2, Nanotechnology 2008: Life Sciences, Medicine & Bio Materials – Technical Proceedings of the 2008 NSTI Nanotechnology Conference and Trade Show, Volume 2
Published: June 1, 2008
Pages: 543 - 546
Industry sectors: Advanced Materials & Manufacturing | Medical & Biotech
Topic: Biomaterials
ISBN: 978-1-4200-8504-4